Loading company…
Mersana Therapeutics develops antibody-drug conjugates for cancer treatment.
Founded in 2001 and based in Cambridge, US, Mersana Therapeutics develops antibody-drug conjugates for cancer. Its platforms include Dolasynthen and Immunosynthen, with candidates at different stages of clinical development. In November 2025, Day One Biopharmaceuticals agreed to acquire the company for USD 129 million upfront, with an additional USD 156 million payable upon milestones.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in